United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - insulin glargine 300 u in 1 ml - toujeo is indicated to improve glycemic control in adults and pediatric patients 6 years of age and older with diabetes mellitus. limitations of use: toujeo is not recommended for the treatment of diabetic ketoacidosis. toujeo is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] . - in patients with hypersensitivity to insulin glargine or any excipients in toujeo [see warnings and precautions (5.5)] . risk summary published studies with use of insulin glargine during pregnancy have not reported a clear association with insulin glargine and adverse developmental outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0.2 unit/kg/day. overall, the effects of insulin glargine did not generally differ from those obser

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin glargine, quantity: 10.91 mg/ml - injection, solution - excipient ingredients: zinc chloride; metacresol; glycerol; sodium hydroxide; hydrochloric acid; water for injections - treatment of diabetes mellitus in patients 6 years of age and older.

Israel - English - Ministry of Health

sanofi israel ltd - insulin glargine - solution for injection - insulin glargine 300 u/ml - insulin glargine - treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years .

European Union - English - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin glargine - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.,

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin glargine, quantity: 32.74 mg - injection, solution - excipient ingredients: metacresol; zinc chloride; glycerol; sodium hydroxide; hydrochloric acid; water for injections - treatment of diabetes mellitus in adults

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - insulin glargine 300 iu/ml equivalent to 10.91 mg/ml - solution for injection - 300 iu/ml - active: insulin glargine 300 iu/ml equivalent to 10.91 mg/ml excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc chloride - treatment of diabetes mellitus in patients 6 years of age and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - insulin glargine 10.91 mg/ml equivalent to 300 iu/ml - solution for injection - 300 iu/ml - active: insulin glargine 10.91 mg/ml equivalent to 300 iu/ml excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc chloride - treatment of diabetes mellitus in adults.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin glargine - solution for injection - 300unit/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi-aventis deutschland gmbh - insulin glargine - solution for injection - 300iu/ml

United States - English - NLM (National Library of Medicine)

a-s medication solutions - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - insulin glargine 300 u in 1 ml - toujeo is indicated to improve glycemic control in adults and pediatric patients 6 years of age and older with diabetes mellitus. limitations of use: toujeo is not recommended for the treatment of diabetic ketoacidosis. toujeo is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] . - in patients with hypersensitivity to insulin glargine or any excipients in toujeo [see warnings and precautions (5.5)] . risk summary published studies with use of insulin glargine during pregnancy have not reported a clear association with insulin glargine and adverse developmental outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0.2 unit/kg/day. overall, the effects of insulin glargine did not generally differ from those obser